Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study
Study limitation reported by the research below: “The ustekinumab comparator arm in Part 2 was small (n=28), reducing the power to detect differences in most outcomes other than PASI100.”